What is NTRA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 56.41B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NTRA?

P/E (TTM) is n/a and 52-week range is $172.82 to $437.41 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NTRA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NTRA?

The company profile lists revenue (TTM) near $2.71B, net income (TTM) near $-19.24B, EPS (TTM) near $-1.37 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Natera Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Austin, Texas, US, 143.2M shares outstanding, ISIN US6323071042 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Natera Inc

$NTRA

Health Care · Biotechnology

IR Run Scenarios

$393.44

-2.80%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 6,135 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

Employees

6,135

Website

www.natera.com/

IPO

2015-07-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)